Novogen Limited (NASDAQ:KZIA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Novogen Limited (NASDAQ:KZIA – Get Free Report) have received an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $25.80.

A number of research analysts have recently issued reports on KZIA shares. Laidlaw initiated coverage on Novogen in a research note on Wednesday, April 15th. They issued a “buy” rating and a $25.00 price objective on the stock. Wall Street Zen cut Novogen from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. BTIG Research initiated coverage on Novogen in a report on Wednesday, July 1st. They issued a “buy” rating and a $34.00 target price for the company. Lake Street Capital began coverage on Novogen in a research note on Thursday, June 11th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st.

Get Novogen alerts:

Read Our Latest Analysis on KZIA

Novogen Price Performance

Shares of KZIA opened at $13.25 on Monday. The firm’s fifty day simple moving average is $13.11 and its two-hundred day simple moving average is $9.50. Novogen has a 12 month low of $4.86 and a 12 month high of $17.40.

Novogen Company Profile

(Get Free Report)

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.

Featured Articles

• Five stocks we like better than Novogen
• Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
• This Under-the-Radar Industrial Is Quietly Powering AI
• Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
• Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares

Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.